Rothschild Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rothschild Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,300	Closed	-$345K	–	47
2015 Q1	$345K	Hold	3,300	–	–	0.15%	35
2014 Q4	$320K	Hold	3,300	–	–	0.15%	35
2014 Q3	$258K	Hold	3,300	–	–	0.12%	37
2014 Q2	$208K	Buy	3,300 +300	+10%	+$17.8K	0.09%	42
2014 Q1	$201K	Hold	3,000	–	–	0.1%	41
2013 Q4	$193K	Buy	+3,000	New	+$179K	0.09%	38

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Rothschild Capital Partners's ALNY Position: Q2 2015 in Review

Rothschild Capital Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2015, closing a stake of 3,300 shares — an estimated $345K sold.

Rothschild Capital Partners first reported a position in ALNY in Q4 2013 and held it in 6 quarters. The position peaked at $345K in Q1 2015. 278 funds tracked by Wall St. Rank hold ALNY as of Q2 2015.

Rothschild Capital Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Rothschild Capital Partners sold 3,300 Alnylam Pharmaceuticals shares in Q2 2015, an estimated $345K.
Rothschild Capital Partners first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Rothschild Capital Partners's Alnylam Pharmaceuticals position peaked at $345K in Q1 2015.
278 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2015.

Based on Rothschild Capital Partners's 13F filing for Q2 2015, filed 31 Jul 2015.